Adicet Bio Inc. (ACET, Financial) experienced a significant stock price drop of 5%. The shares are currently trading at $1.14, with a transaction volume of 380,451 shares, a turnover rate of 0.46%, and a price volatility of 4.92%.
Recent financial reports reveal zero operating revenue, a net loss of $30.48 million, earnings per share of -$0.34, a gross loss of $1.59 million, and a price-to-earnings ratio of -0.68. Despite the challenging financial metrics, 75% of the eight institutions involved in the stock rating have recommended buying, with the remaining 25% suggesting holding. No institution advised selling.
The biotechnology sector, where Adicet Bio operates, saw an overall decline of 0.35%. Among its peers, Nkgen Biotech Inc, Pulmatrix Inc, and Calidi Biotherapeutics Inc posted notable gains. High turnover rates were observed in Cyclacel Pharmaceuticals Inc, Elevai Labs Inc, and Calidi Biotherapeutics Inc, showing figures of 538.36%, 404.58%, and 146.05% respectively. Noteworthy price fluctuations were recorded for Psyence Biomedical Ltd, Celularity Inc, and Cero Therapeutics Holdings Inc, with amplitudes of 129.00%, 73.71%, and 71.97% respectively.
Adicet Bio is a clinical-stage biotechnology company specializing in the discovery and development of allogeneic gamma delta T cell therapies for cancer and other diseases. Their leading product, ADI-001, targets CD20 for autoimmune diseases and aggressive B-cell non-Hodgkin's lymphoma. The pipeline also includes ADI-270, an armored gamma delta CAR-T cell candidate targeting renal cell carcinoma and other CD70+ solid tumors and hematological malignancies.
